NO20061171L - Quinazolin analoger som reseptor tyroson kinase inhibitorer - Google Patents

Quinazolin analoger som reseptor tyroson kinase inhibitorer

Info

Publication number
NO20061171L
NO20061171L NO20061171A NO20061171A NO20061171L NO 20061171 L NO20061171 L NO 20061171L NO 20061171 A NO20061171 A NO 20061171A NO 20061171 A NO20061171 A NO 20061171A NO 20061171 L NO20061171 L NO 20061171L
Authority
NO
Norway
Prior art keywords
tyrosine kinase
kinase inhibitors
receptor tyrosine
quinazoline
quinazoline analogues
Prior art date
Application number
NO20061171A
Other languages
English (en)
Other versions
NO336275B1 (no
Inventor
Eli Wallace
George Topalov
Joseph Lyssikatos
Alexandre Buckmelter
Qian Zhao
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/642,440 external-priority patent/US7501427B2/en
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of NO20061171L publication Critical patent/NO20061171L/no
Publication of NO336275B1 publication Critical patent/NO336275B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Abstract

Det beskrives quinazolinanaloger med formel I:. der A er bundet til minst et av karbonene i 5-, 6-, 7- eller 8-posisjon på den bicykliske ring, og ringen er substituert med opptil to uavhengige Rgrupper.Det beskrives videre metoder for å anvende forbindelsene med formel I som type I reseptor tyrosin kinaseinhibitorer og for behandling av hyperproliferative sykdommer som cancer.
NO20061171A 2003-08-14 2006-03-13 Forbindelse, angitt som quinazolinanalog som reseptor tyrosin kinaseinhibitor, anvendelse derav for fremstilling av et medikament, samt farmasøytisk sammensetning omfattende forbindelsen NO336275B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/642,440 US7501427B2 (en) 2003-08-14 2003-08-14 Quinazoline analogs as receptor tyrosine kinase inhibitors
US55171804P 2004-03-10 2004-03-10
PCT/US2004/026235 WO2005016346A1 (en) 2003-08-14 2004-08-10 Quinazoline analogs as receptor tyrosine kinase inhibitors

Publications (2)

Publication Number Publication Date
NO20061171L true NO20061171L (no) 2006-04-10
NO336275B1 NO336275B1 (no) 2015-07-06

Family

ID=34198338

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061171A NO336275B1 (no) 2003-08-14 2006-03-13 Forbindelse, angitt som quinazolinanalog som reseptor tyrosin kinaseinhibitor, anvendelse derav for fremstilling av et medikament, samt farmasøytisk sammensetning omfattende forbindelsen

Country Status (24)

Country Link
US (2) US7452895B2 (no)
EP (1) EP1660090B1 (no)
JP (1) JP4828421B2 (no)
KR (2) KR101028952B1 (no)
CN (3) CN103664802B (no)
AR (1) AR045378A1 (no)
AU (1) AU2004264937B2 (no)
BR (1) BRPI0413565B8 (no)
CA (1) CA2535614C (no)
CL (1) CL2004002066A1 (no)
CY (1) CY1113992T1 (no)
DK (1) DK1660090T3 (no)
ES (1) ES2399427T3 (no)
HK (1) HK1085400A1 (no)
IL (1) IL173593A (no)
IS (1) IS8288A (no)
MX (1) MXPA06001767A (no)
NO (1) NO336275B1 (no)
NZ (1) NZ545459A (no)
PL (1) PL1660090T3 (no)
PT (1) PT1660090E (no)
RU (1) RU2350605C2 (no)
TW (1) TWI353982B (no)
WO (1) WO2005016346A1 (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7488823B2 (en) * 2003-11-10 2009-02-10 Array Biopharma, Inc. Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
KR101028952B1 (ko) 2003-08-14 2011-04-12 어레이 바이오파마 인크. 수용체 티로신 키나아제 억제제로서의 퀴나졸린 유사체
CA2755268C (en) 2005-11-15 2013-12-31 Array Biopharma, Inc. Erbb inhibitors
BR112014009084B1 (pt) 2011-10-14 2021-09-21 Array Biopharma Inc Polimorfos cristalinos de arry-380
WO2013056108A2 (en) 2011-10-14 2013-04-18 Array Biopharma Inc. Solid dispersion
CA2867723C (en) 2012-03-23 2022-11-08 Array Biopharma Inc. Treatment of brain cancer
KR20180043356A (ko) * 2015-09-04 2018-04-27 아슬란 파마슈티컬스 피티이 엘티디 담관암의 치료법
US20190134034A1 (en) * 2016-04-21 2019-05-09 Aslan Pharmaceuticals Pte. Ltd. Method of Treating Liver Cancer
GB201611580D0 (en) * 2016-07-01 2016-08-17 Aslan Pharmaceuticals Pte Ltd Method
CN106349231A (zh) * 2016-08-09 2017-01-25 浙江医药高等专科学校 一类含卤代噻吩磺酰胺结构的苯并喹唑啉类酪氨酸激酶抑制剂
CN106317039A (zh) * 2016-08-09 2017-01-11 浙江医药高等专科学校 一种含噻吩磺酰胺结构的乙氧苯并喹唑啉类酪氨酸激酶抑制剂、制备方法及用途
CN106317040A (zh) * 2016-08-09 2017-01-11 浙江医药高等专科学校 含噻吩磺酰胺结构的苯并喹唑啉类酪氨酸激酶抑制剂、制备方法及用途
CN106349230A (zh) * 2016-08-09 2017-01-25 浙江医药高等专科学校 一种含硝基噻吩磺酰胺结构的苯并喹唑啉类酪氨酸激酶抑制剂及用途
CN106279135A (zh) * 2016-08-09 2017-01-04 浙江医药高等专科学校 一种噻吩磺酰胺结构的苯并喹唑啉类酪氨酸激酶抑制剂
CN109923129A (zh) 2016-08-26 2019-06-21 新加坡科技研究局 巨噬细胞刺激蛋白受体（或RON-Recepteur d,Origine Nantais）抗体及其用途
EP3589286B1 (en) 2017-03-02 2022-08-03 ASLAN Pharmaceuticals Pte Ltd Dhodh inhibitor for treating haematological cancer
CA3060407A1 (en) 2017-04-28 2018-11-01 Seattle Genetics, Inc. Treatment of her2 positive cancers
WO2018222135A1 (en) 2017-06-02 2018-12-06 Aslan Pharmaceuticals Pte Ltd Cancer therapy
WO2018222134A1 (en) 2017-06-02 2018-12-06 Aslan Pharmaceuticals Pte Ltd Cancer therapy
FI3853220T3 (fi) 2018-09-18 2024-02-22 Hoffmann La Roche Kinatsoliinijohdannaisia antitumoraalisina aineina
EP3864014B1 (en) * 2018-10-09 2023-07-05 ASLAN Pharmaceuticals Pte Ltd Malonate salt of varlitinib
CN111499622B (zh) * 2019-07-08 2023-06-06 山东省科学院菏泽分院 一种治疗胆管癌的药物的制备方法
TW202214641A (zh) 2020-06-30 2022-04-16 美商艾瑞生藥股份有限公司 Ｈｅｒ２突變抑制劑
TW202345816A (zh) * 2022-03-28 2023-12-01 大陸商江蘇恆瑞醫藥股份有限公司 含氮雜環類化合物、其製備方法及其在醫藥上的應用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2583774A (en) * 1948-04-30 1952-01-29 Merck & Co Inc Vitamin b6 derivatives
BE795970A (fr) * 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
CA1340821C (en) * 1988-10-06 1999-11-16 Nobuyuki Fukazawa Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components
US5204348A (en) 1988-10-06 1993-04-20 Mitsui Toatsu Chemicals Inc. Heterocyclic compounds and anticancer-drug potentiaters conaining them as effective components
US5502187A (en) * 1992-04-03 1996-03-26 The Upjohn Company Pharmaceutically active bicyclic-heterocyclic amines
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (no) 1994-11-12 1997-12-01 Zeneca Ltd
GB9424233D0 (en) 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
HUP9901155A3 (en) 1996-02-13 2003-04-28 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
CN100503580C (zh) * 1996-04-12 2009-06-24 沃尼尔·朗伯公司 酪氨酸激酶的不可逆抑制剂
DE69716916T2 (de) 1996-07-13 2003-07-03 Glaxo Group Ltd Kondensierte heterozyklische verbindungen als protein kinase inhibitoren
US6225318B1 (en) 1996-10-17 2001-05-01 Pfizer Inc 4-aminoquinazolone derivatives
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
JP2001522853A (ja) 1997-11-11 2001-11-20 ファイザー・プロダクツ・インク 抗癌剤として有用なチエノピリミジンおよびチエノピリジン誘導体
EP1066039A4 (en) 1998-03-02 2003-02-26 Cocensys Inc SUBSTITUTED QUINAZOLINE AND THEIR ANALOGS AND USES
US6017922A (en) * 1998-05-18 2000-01-25 U.S. Bioscience, Inc. Thermally stable trimetrexates and processes for producing the same
GEP20032997B (en) 1998-11-19 2003-06-25 Warner Lambert Co N-[4-(3-Chloro-4-Fluoro-Phenylamino)-7-(3-Morpholin-4-Yl-Propoxy)-Quinazolin-6-Yl]-crylamide, as an Irreversible Inhibitor of Tyrosine Kinases
CZ20012498A3 (cs) 1999-01-13 2002-08-14 Warner-Lambert Company Benzoheterocyklické sloučeniny a jejich pouľití jako inhibitorů MEK
PT1154774E (pt) * 1999-02-10 2005-10-31 Astrazeneca Ab Derivados de quinazolina como inibidores de angiogenese
KR20020032608A (ko) 1999-09-21 2002-05-03 다비드 에 질레스 퀴나졸린 화합물 및 이를 함유하는 제약 조성물
GB9922171D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
EP1257526B1 (en) * 2000-02-17 2005-05-11 Bristol-Myers Squibb Company Aniline-derived ligands for the thyroid receptor
MXPA02012034A (es) 2000-06-06 2003-04-25 Pfizer Prod Inc Derivados de tiofeno utiles como agentes anticancerosos.
OA12291A (en) 2000-06-22 2004-03-18 Pfizer Prod Inc Substituted bicyclic derivatives for the treatmentof abnormal cell growth.
PT1294715E (pt) 2000-06-30 2007-05-31 Glaxo Group Ltd Compostos do sal de ditosilato de quinazolina
US7265134B2 (en) 2001-08-17 2007-09-04 Merck & Co., Inc. Tyrosine kinase inhibitors
AU2002361577A1 (en) 2001-10-30 2003-05-12 Merck And Co., Inc. Tyrosine kinase inhibitors
KR20050042055A (ko) * 2001-11-03 2005-05-04 아스트라제네카 아베 항종양제로서의 퀴나졸린 유도체
CN100491372C (zh) * 2001-12-24 2009-05-27 阿斯特拉曾尼卡有限公司 作为欧若拉激酶抑制剂的取代喹唑啉衍生物
US7488823B2 (en) 2003-11-10 2009-02-10 Array Biopharma, Inc. Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
EP1594504A4 (en) 2003-01-23 2008-12-17 T K Signal Ltd NEW IRREVERSIBLE EGF RECEPTOR TYROSINE KINASE INHIBITORS AND THEIR USES FOR THERAPEUTIC AND DIAGNOSTIC PURPOSES
PE20040945A1 (es) * 2003-02-05 2004-12-14 Warner Lambert Co Preparacion de quinazolinas substituidas
WO2004106308A1 (en) * 2003-05-27 2004-12-09 Pfizer Products Inc. Quinazolines and pyrido [3,4-d] pyrimidines as receptor tyrosine kinase inhibitors
KR101028952B1 (ko) 2003-08-14 2011-04-12 어레이 바이오파마 인크. 수용체 티로신 키나아제 억제제로서의 퀴나졸린 유사체
US7501427B2 (en) * 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
KR20060037447A (ko) 2003-08-18 2006-05-03 화이자 프로덕츠 인크. ｅｒｂＢ２ 항암제에 대한 투약 스케쥴
WO2005044302A1 (en) 2003-11-06 2005-05-19 Pfizer Products Inc. Selective erbb2 inhibitor/anti-erbb antibody combinations in the treatment of cancer
KR100735639B1 (ko) 2004-12-29 2007-07-04 한미약품 주식회사 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법
CA2755268C (en) 2005-11-15 2013-12-31 Array Biopharma, Inc. Erbb inhibitors

Also Published As

Publication number Publication date
CN103664802B (zh) 2015-08-05
RU2006103493A (ru) 2007-09-20
CN102432552A (zh) 2012-05-02
TWI353982B (en) 2011-12-11
CL2004002066A1 (es) 2005-06-03
EP1660090A4 (en) 2008-12-03
CN103772373B (zh) 2017-06-09
TW200519096A (en) 2005-06-16
PT1660090E (pt) 2013-01-11
US20050043334A1 (en) 2005-02-24
IL173593A0 (en) 2006-07-05
BRPI0413565A (pt) 2006-10-17
KR100953246B1 (ko) 2010-04-16
AR045378A1 (es) 2005-10-26
WO2005016346A1 (en) 2005-02-24
NZ545459A (en) 2009-12-24
CA2535614C (en) 2009-12-22
CN102432552B (zh) 2016-01-20
CA2535614A1 (en) 2005-02-24
ES2399427T3 (es) 2013-04-01
KR20060064630A (ko) 2006-06-13
US7452895B2 (en) 2008-11-18
NO336275B1 (no) 2015-07-06
EP1660090B1 (en) 2012-11-21
EP1660090A1 (en) 2006-05-31
PL1660090T3 (pl) 2013-04-30
MXPA06001767A (es) 2006-05-12
CY1113992T1 (el) 2016-07-27
KR20100018079A (ko) 2010-02-16
HK1085400A1 (en) 2006-08-25
CN103772373A (zh) 2014-05-07
DK1660090T3 (da) 2012-12-17
AU2004264937B2 (en) 2010-04-29
US20090048279A1 (en) 2009-02-19
JP4828421B2 (ja) 2011-11-30
IL173593A (en) 2011-11-30
IS8288A (is) 2006-02-07
AU2004264937A1 (en) 2005-02-24
BRPI0413565B8 (pt) 2021-05-25
BRPI0413565B1 (pt) 2019-10-01
KR101028952B1 (ko) 2011-04-12
JP2007502295A (ja) 2007-02-08
US8278314B2 (en) 2012-10-02
CN103664802A (zh) 2014-03-26
RU2350605C2 (ru) 2009-03-27

Similar Documents

Publication Publication Date Title
NO20061171L (no) Quinazolin analoger som reseptor tyroson kinase inhibitorer
NO20062763L (no) Pyrrolotriazinforbindelser som kinaseinhibitorer
NO20061322L (no) Kinazolinderivater som tyrosin kinase inhibitorer
MXPA05000715A (es) Inhibidores novedosos de cinasas.
BRPI0412347A (pt) 2-aminofenil-4-fenilpiridinas como inibidores de quinase
YU34202A (sh) Stabilni polimorf n-(3-etinilfenilamino)-6,7-bis(2- metoksietoksi)-4-kvinazolinamin hidrohlorida, postupci proizvodnje i njegova farmaceutska upotreba
EA200401378A1 (ru) N-замещенные трициклические 3-аминопиразолы в качестве ингибиторов pdgf рецептора
NO20061323L (no) Kinazolinderivater
PE20021010A1 (es) Derivados espirociclicos como inhibidores de fosfodiesterasa-7
PE20040999A1 (es) Nuevas pirazolopirimidinas como inhibidores de cinasas dependientes de ciclinas
DK1678166T3 (da) Proteinkinaseinhibitorer
MXPA06009475A (es) Derivados de quinazolina y usos terapeuticos de los mismos.
WO2006007378A3 (en) Pyrrolotriazine kinase inhibitors
NO20090581L (no) Hydroksylerte og metoksylerte syklopenta[D]pyrimidiner som AKT-proteinkinaseinhibitorer
WO2004001059A3 (en) Heterocyclic inhibitors of kinases
ATE482212T1 (de) Pyrrolotriazinverbindungen
PE20060504A1 (es) Derivados de pirimidina en el tratamiento de cancer
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
EA200400466A1 (ru) Производные пиперазина с антагонистической активностью к рецептору ccr1
ECSP088293A (es) Inhibidores de gamma secretasa, de sulfonamido n-cíclico puenteado
ECSP077992A (es) Derivados de tienopirimidina y tienopiridina como inhibidores de tirosina cinasa 3 tipo fms
ATE386530T1 (de) Chinazoline derivate und ihre anwendung in der krebsbehandlung
HUP0101818A1 (hu) N-(3-etinil-fenil)-6,7-bisz(2-metoxietoxi)-4-kinazolinamin-mezilát anhidrát és monohidrát és a vegyületet tartalmazó gyógyászati készítmények
ATE337001T1 (de) Antitumorverbindung und ihre therapeutischen verwendungen
DK1448562T3 (da) Substituerede tetracycliske pyrroloquinolonderivater egnede som phosphodiesteraseinhibitorer